The prognosis for chondrosarcoma depends on a number of factors, including the tumor's stage and the degree of surgical success, according to the Liddy Shriver Sarcoma Institute. Most low-grade tumors can be successfully removed with little chance of recurrence. The highest-risk chondrosarcoma, de-differentiated tumors, have the highest risk of metastasis and recurrence, along with a poor survival rate.
Conventional chondrosarcoma and clear-cell chondrosarcoma tend to remain localized and less aggressive, says the Liddy Shriver Sarcoma Institute. High-grade tumors, usually the dedifferentiated and mesenchymal chondrosarcoma types, behave aggressively and often spread.
Dedifferentiated chondrosarcoma, usually found in the arm, leg or pelvis, is the most difficult to treat and reports the poorest prognosis, states the Liddy Shriver Sarcoma Institute. This type of the condition often includes a low-grade tumor next to a high-grade tumor. Dedifferentiated chondrosarcoma constitutes only 10 percent of chondrosarcoma cases.
Except for mesenchymal chondrosarcoma, standard cancer treatments such as chemotherapy and radiation have little effect on chrondrosarcoma, explains the Liddy Shriver Sarcoma Institute. The standard treatment is surgery to remove the tumor. Removing all of the tumor is key to a good prognosis.
Chondrosarcoma most often strikes men between the ages of 20 and 60, reports the Liddy Shriver Sarcoma Institute. It is relatively rare, comprising 20 percent of bone tumor cases each year in the United States.